Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Oakville, Ontario--(Newsfile Corp. - November 14, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced that on November 14, 2022, it received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Company's Class A common shares ("Common Shares") for the 30 consecutive business days prior to the date of the Notice.
安大略省奧克維爾-(Newsfile Corp.-2022年11月14日)-心臟治療公司(納斯達克：CRDL) (多倫多證券交易所：CRDL) (《心型》或“公司”)，一家專注於研究和臨牀開發治療心臟病的抗炎和抗纖維化療法的臨牀期生命科學公司)宣佈，2022年11月14日，它收到了納斯達克股票市場有限責任公司(以下簡稱納斯達克)的通知(簡稱：通知)，聲明本公司並未遵守納斯達克上市規則第5550(A)(2)條所訂的每股1.00美元之最低投標價格規定(“最低投標要求”)，該等最低投標價格乃以本公司A類普通股(“普通股”)於通知日期前連續30個營業日之收市價為基準。
The Notice has no immediate effect on the listing or trading of the Common Shares on Nasdaq, and the Company's operations are not affected by the receipt of the Notice. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days from the date of the Notice, or until May 15, 2023, to regain compliance with the Minimum Bid Requirement, during which time the Common Shares will continue to trade on Nasdaq. If at any time before May 15, 2023, the bid price of the Common Shares closes at or above US$1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Requirement by May 15, 2023, the Company may be eligible, upon satisfaction of certain Nasdaq listing requirements, for an additional period of 180 calendar days to regain compliance or the Common Shares may be subject to delisting from Nasdaq.
該通知對普通股在納斯達克的上市或交易並無即時影響，本公司的經營亦不受收到該通知的影響。根據納斯達克上市規則第5810(C)(3)(A)條，本公司有180個歷日，自公告日期起，或至2023年5月15日，恢復遵守最低投標要求，在此期間，普通股將繼續在納斯達克交易。如果在2023年5月15日之前的任何時間，普通股的投標價格連續10個工作日收於每股1.00美元或以上，公司將重新遵守最低投標要求。若本公司未能於2023年5月15日前恢復遵守最低投標要求，本公司可能有資格在滿足若干納斯達克上市要求後，再申請180個歷日的額外期限以恢復遵守要求，否則本公司普通股可能會被納斯達克摘牌。
The Company will closely monitor the situation and is considering various strategies to regain compliance with the Minimum Bid Requirement under the Nasdaq Listing Rules. This notice does not have any impact on the Company's TSX listing.
公司將密切關注事態發展，並正在考慮各種策略，以重新遵守納斯達克上市規則下的最低投標要求。本公告對本公司在多倫多證券交易所的上市沒有任何影響。
About Cardiol Therapeutics
關於心臟治療學
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The Company's lead product candidate, CardiolRx™, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
心臟治療公司(納斯達克代碼：CRDL)(多倫多證券交易所市場代碼：CRDL)是一家臨牀階段的生命科學公司，專注於心髒疾病抗炎和抗纖維化療法的研究和臨牀開發。該公司的主要候選產品--心臟olRx™是一種藥物製造的口服大麻二醇配方，正在開發用於心臟病的臨牀藥物。眾所周知，大麻二醇抑制炎症體途徑的激活，這是一個已知在心肌炎、心包炎和心力衰竭相關的炎症和纖維化中發揮重要作用的細胞內過程。
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the "ARCHER" trial) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age; and (ii) a Phase II multi-center open-label pilot study in recurrent pericarditis (inflammation of the pericardium), which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
HEADOL已獲得美國食品和藥物管理局的新藥申請授權，將進行臨牀研究，以評估™在兩種影響心臟的疾病中的有效性和安全性：(I)第二階段多國、隨機、雙盲、安慰劑對照試驗(射手試驗)治療急性心肌炎，這是年輕人急性和暴發性心力衰竭的重要原因，也是35歲以下人羣心源性猝死的主要原因；以及(Ii)一項關於複發性心包炎(心包炎)的第二階段多中心開放標籤試點研究，它與衰弱的胸痛、呼吸急促和疲勞等症狀有關，並導致身體受限、生活質量降低、急診科就診和住院。
Cardiol is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure - a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
心臟公司還在開發一種用於治療心力衰竭的新型皮下給藥大麻二醇藥物配方。心力衰竭是發達國家導致死亡和住院的主要原因，美國每年的相關醫療費用超過300億美元。
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
欲獲知更多有關心臟治療公司的信息，請訪問：core olrx.com。
Cautionary statement regarding forward-looking information:
有關前瞻性信息的警示聲明：
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to, statements relating to the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, the molecular targets and mechanism of action of our product candidates, the Company's intended clinical study and trial activities and timelines associated with such activities, and the Company's plan to advance the development of a novel subcutaneous formulation of CardiolRx™ for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form dated March 23, 2022, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise.
本新聞稿包含適用證券法所指的“前瞻性信息”。除有關歷史事實的陳述外，所有涉及卡迪爾相信、預期或預期未來將、可能、可能或可能發生的活動、事件或發展的陳述均為“前瞻性信息”。本文包含的前瞻性信息可能包括但不限於有關該公司致力於開發治療心臟病的抗炎和抗纖維化療法的陳述、我們候選產品的分子靶標和作用機制、該公司計劃進行的臨牀研究和試驗活動以及與這些活動相關的時間表，以及該公司推進用於治療心力衰竭的新型皮下製劑HearolRx™的計劃。本文包含的前瞻性信息反映了基於目前掌握的信息、基於某些假設和基於各種已知和未知的風險、不確定因素以及其他因素，可能會導致實際事件或結果與前瞻性信息明示或暗示的任何未來結果、業績或成就大不相同的當前預期或信念，並且不(也不應被視為)對未來業績的保證。這些風險、不確定因素和其他因素包括公司日期為2022年3月23日的年度信息表格中提到的風險和不確定因素，以及與產品商業化和臨牀研究相關的風險和不確定因素。這些假設、風險、不確定性和其他因素應仔細考慮，投資者不應過度依賴前瞻性信息。, 而這些信息可能不適合用於其他目的。任何前瞻性信息僅説明截至本新聞稿發佈之日，除非適用的證券法可能要求，否則，無論是由於新信息、未來事件或結果或其他原因，卡迪爾公司都不打算或有義務更新或修改此類前瞻性信息。
For further information, please contact:
如需更多信息，請聯繫：
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com
投資者關係部特雷弗·伯恩斯電話：+1-289-910-0855
郵箱：trevor.burns@core olrx.com
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。